Acorda Therapeutics

About:

Acorda Therapeutics began in 1995 as a network of scientists, physicians and business people with a common belief.

Website: http://www.acorda.com/

Twitter/X: AcordaNews

Top Investors: Novartis Venture Fund, National Institute of Neurological Disorders and Stroke, Forbion Capital Partners, MPM Capital, New York State Department of Health

Description:

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.